
Syed Shahzad Hasan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4338880/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Oxygen Therapy may be Beneficial to Patients with COVID-19 and Underlying Pulmonary Diseases. Journal of Asthma, 2023, 60, 422-423.	1.7	2
2	Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: a meta-analysis. Journal of Asthma, 2022, 59, 787-790.	1.7	10
3	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Review of Anti-Infective Therapy, 2022, 20, 211-229.	4.4	10
4	The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2022, 22, 167-181.	2.2	24
5	Use of Calcium Channel Blockers and the Risk of All-cause Mortality and Severe Illness in Patients With COVID-19: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2022, 79, 199-205.	1.9	4
6	Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic. Irish Journal of Medical Science, 2022, 191, 1667-1668.	1.5	2
7	Antibiotic consumption among hospitalized neonates and children in Punjab province, Pakistan. Expert Review of Anti-Infective Therapy, 2022, 20, 931-939.	4.4	24
8	Insulin therapy in patients with COVID-19. Acta Diabetologica, 2022, 59, 285-286.	2.5	0
9	Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Anti-Infective Therapy, 2022, 20, 567-575.	4.4	6
10	Has it come to the time to recommend routine use of alirocumab in patients with acute coronary syndrome?. European Journal of Preventive Cardiology, 2022, 29, e77-e78.	1.8	0
11	IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?. Cytokine, 2022, 149, 155730.	3.2	2
12	Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. Hypertension Research, 2022, 45, 360-363.	2.7	13
13	Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity. European Journal of Preventive Cardiology, 2022, 28, e52-e52.	1.8	1
14	The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacology and Immunotoxicology, 2022, 44, 28-34.	2.4	16
15	Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant. Journal of NeuroImmune Pharmacology, 2022, 17, 425-426.	4.1	1
16	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy, 2022, 28, 257-265.	1.7	18
17	Physiological plausibility of lower viral load in patients with COVIDâ€19 and olfactory/gustatory dysfunction. Clinical Otolaryngology, 2022, 47, 397-398.	1.2	1
18	Future of antivirals in COVID-19: The case of favipiravir. International Immunopharmacology, 2022, 103, 108455.	3.8	5

#	Article	IF	CITATIONS
19	Potential applications and performance of machine learning techniques and algorithms in clinical practice: A systematic review. International Journal of Medical Informatics, 2022, 159, 104679.	3.3	40
20	The use of tenofovir in patients with COVIDâ€19. HIV Medicine, 2022, 23, 807-808.	2.2	2
21	Evaluation of general practice pharmacists' role by key stakeholders in England and Australia. Journal of Pharmaceutical Health Services Research, 2022, 13, 31-40.	0.6	5
22	The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. Inflammopharmacology, 2022, 30, 149-157.	3.9	3
23	Metformin in COVID-19: clinical trials are needed to prove its benefits. Irish Journal of Medical Science, 2022, 191, 2641-2642.	1.5	2
24	Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure. Revista Clínica Espanõla, 2022, , .	0.5	2
25	The effectiveness of mRNAâ€1273 vaccine against COVIDâ€19 caused by Delta variant: A systematic review and metaâ€analysis. Journal of Medical Virology, 2022, 94, 2269-2274.	5.0	14
26	Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis. Primary Care Diabetes, 2022, 16, 271-278.	1.8	2
27	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100101.	1.0	8
28	Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19. High Blood Pressure and Cardiovascular Prevention, 2022, , 1.	2.2	0
29	Antimicrobial consumption in hospitalised COVID-19 patients: a systematic review and meta-analysis. International Journal of Pharmacy Practice, 2022, 30, i5-i6.	0.6	2
30	Risk of severe illness in patients infected with SARS-CoV-2 of Delta variant: a systematic review and meta-analysis. Infectious Diseases, 2022, 54, 614-617.	2.8	6
31	Use of sulforaphane in COVID-19: Clinical trials are needed. Molecular Immunology, 2022, 145, 78-79.	2.2	6
32	The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVIDâ€19: A metaâ€analysis of randomized trials. Immunity, Inflammation and Disease, 2022, 10, 255-264.	2.7	15
33	Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 2022, 20, 749-772.	4.4	46
34	The effect of curcumin on the risk of mortality in patients with <scp>COVID</scp> â€19: A systematic review and metaâ€analysis of randomized trials. Phytotherapy Research, 2022, 36, 3365-3368.	5.8	6
35	A pharmacist-led educational intervention to improve nebulization-related knowledge and practices of nursing staff: a pre–post interventional study from Pakistan. Drugs and Therapy Perspectives, 2022, 38, 194-200.	0.6	0
36	Impact of medication reviews on potentially inappropriate medications and associated costs among older women in aged care. Research in Social and Administrative Pharmacy, 2022, , .	3.0	2

#	Article	IF	CITATIONS
37	Angiotensin Receptor and Neprilysin Inhibitors for COVID-19 Treatment and Personalized Medicine?. OMICS A Journal of Integrative Biology, 2022, 26, 318-319.	2.0	Ο
38	Can COVID-19 vaccines improve cardiovascular outcomes?. Travel Medicine and Infectious Disease, 2022, 48, 102350.	3.0	3
39	Development, validation and evaluation of an online medication review tool (MedReview). PLoS ONE, 2022, 17, e0269322.	2.5	2
40	Effects of Angiotensin II Receptor Blockers on the Risk of Mortality in Patients with COVID-19: An Updated Systematic Review and Meta-analysis of Randomized Trials. American Journal of Hypertension, 2022, 35, 763-764.	2.0	2
41	"Sehat Sahulat Program― A Leap into the Universal Health Coverage in Pakistan. International Journal of Environmental Research and Public Health, 2022, 19, 6998.	2.6	14
42	Management of Comedication in Hospitalized COVID-19 Patients With Atrial Fibrillation. Hospital Pharmacy, 2021, 56, 629-632.	1.0	0
43	Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes. International Journal of Clinical Pharmacy, 2021, 43, 621-628.	2.1	4
44	Common combinations of medications used among oldest-old women: a population-based study over 15Âyears. Aging Clinical and Experimental Research, 2021, 33, 1919-1928.	2.9	2
45	Corticosteroid-related In-Hospital Hyperglycemia: Does It Negate Mortality Benefits in Coronavirus Disease 2019?. Clinical Infectious Diseases, 2021, 73, e2848-e2849.	5.8	10
46	Social distancing and the use of PPE by community pharmacy personnel: Does evidence support these measures?. Research in Social and Administrative Pharmacy, 2021, 17, 456-459.	3.0	34
47	Could melatonin be used in COVIDâ€19 patients with laryngopharyngeal reflux disease?. Journal of Medical Virology, 2021, 93, 92-93.	5.0	2
48	Pharmacologic therapeutic options for thromboprophylaxis in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 29-30.	2.1	7
49	Pharmacological Management of Obese Patients with Type 2 Diabetes amid COVID-19 Pandemic. Obesity Surgery, 2021, 31, 413-414.	2.1	2
50	Personal protective practices and pharmacy services delivery by community pharmacists during COVID-19 pandemic: Results from a national survey. Research in Social and Administrative Pharmacy, 2021, 17, 1832-1837.	3.0	45
51	Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?. Pulmonology, 2021, 27, 86-87.	2.1	3
52	Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients. European Journal of Hospital Pharmacy, 2021, 28, 42-46.	1.1	8
53	Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Revista Espanola De Cardiologia (English Ed), 2021, 74, 200-201.	0.6	0
54	Revascularization strategy in patients with acute ST-elevation myocardial infarction amid COVID-19 pandemic. Journal of the Formosan Medical Association, 2021, 120, 772-773.	1.7	0

#	Article	IF	CITATIONS
55	The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19. Revista Espanola De Cardiologia (English Ed), 2021, 74, 114-115.	0.6	6
56	Are severe asthma patients at higher risk of developing severe outcomes from COVIDâ€19?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 959-960.	5.7	15
57	Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert Opinion on Pharmacotherapy, 2021, 22, 229-240.	1.8	14
58	Use of proton pump inhibitors and risk of adverse clinical outcomes from COVIDâ€19: a metaâ€analysis. Journal of Internal Medicine, 2021, 289, 125-128.	6.0	31
59	Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19. European Journal of Clinical Pharmacology, 2021, 77, 435-437.	1.9	10
60	Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?. European Heart Journal, 2021, 42, 2609-2610.	2.2	2
61	Macrolides for patients with COVID-19 and concurrent pertussis infection. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115245.	1.8	1
62	CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke. Clinical Drug Investigation, 2021, 41, 115-116.	2.2	2
63	Use of DPP-4 inhibitors in patients with COVID-19. Acta Diabetologica, 2021, 58, 245-246.	2.5	6
64	The use of combined hormonal contraceptives amid the COVID-19 pandemic. European Journal of Contraception and Reproductive Health Care, 2021, 26, 85-86.	1.5	3
65	Prochlorperazine for nausea and vomiting accompanied COVIDâ€19. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 524-525.	2.8	4
66	Effect of remdesivir on mortality in patients with COVIDâ€19: A metaâ€analysis of randomized control trials. Journal of Medical Virology, 2021, 93, 1860-1861.	5.0	9
67	Azithromycin in patients with COVID-19: Friend or foe?. Clinical Microbiology and Infection, 2021, 27, 136-137.	6.0	5
68	Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic. Expert Review of Cardiovascular Therapy, 2021, 19, 99-100.	1.5	1
69	Use of potentially inappropriate medications among older outpatients and inpatients in a tertiary care hospital in Malaysia. International Journal of Clinical Practice, 2021, 75, e13714.	1.7	5
70	Revascularization in COVIDâ€19 patients with renal infarction. American Journal of Transplantation, 2021, 21, 1345-1345.	4.7	0
71	The use of antimotility drugs in COVID-19 associated diarrhea. Journal of Infection, 2021, 82, e19.	3.3	9
72	Mortality risk with preadmission metformin use in patients with COVIDâ€19 and diabetes: A metaâ€analysis. Journal of Medical Virology, 2021, 93, 695-697.	5.0	68

#	Article	IF	CITATIONS
73	Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19. Rheumatology International, 2021, 41, 677-678.	3.0	8
74	Quality versus Risk-of-Bias assessment in clinical research. Journal of Clinical Epidemiology, 2021, 129, 172-175.	5.0	39
75	Persistent fatigue in patients with COVID-19. Clinical Medicine, 2021, 21, e117-e117.	1.9	2
76	Potential Drug-Drug Interactions Between Interleukin-6 Inhibitors and Pharmacologic Agents for Opioid Use Disorder. primary care companion for CNS disorders, The, 2021, 23, .	0.6	0
77	Insulin Treatment May Not Be Associated with Increased Mortality in Patients with COVID-19 and Concurrent Diabetes. Endocrine Research, 2021, 46, 51-52.	1.2	3
78	The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1089-1094.	1.9	25
79	COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK. Expert Review of Respiratory Medicine, 2021, 15, 973-978.	2.5	8
80	Could it be that the B.1.1.7 lineage is more deadly?. Infection Control and Hospital Epidemiology, 2021, , 1-1.	1.8	4
81	The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological Reports, 2021, 73, 1473-1479.	3.3	25
82	Do sleep quality and sleep duration before or after COVID-19 vaccination affect antibody response?. Chronobiology International, 2021, 38, 941-943.	2.0	10
83	Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019. Journal of Attention Disorders, 2021, , 108705472199755.	2.6	6
84	Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. Journal of Thrombosis and Thrombolysis, 2021, 52, 646-653.	2.1	32
85	Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. DARU, Journal of Pharmaceutical Sciences, 2021, 29, 217-221.	2.0	56
86	Potential interactions between COVID-19 vaccines and antiepileptic drugs. Seizure: the Journal of the British Epilepsy Association, 2021, 86, 80-81.	2.0	17
87	Prasugrel Versus Ticagrelor in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2021, 77, 1483-1484.	2.8	1
88	Association of frailty and mortality in patients with COVID-19: a meta-analysis. British Journal of Anaesthesia, 2021, 126, e108-e110.	3.4	13
89	Effect of COVID-19 on viral hepatitis services in Pakistan. The Lancet Gastroenterology and Hepatology, 2021, 6, 163-164.	8.1	4
90	Prevalence and association of continuous polypharmacy and frailty among older women: A longitudinal analysis over 15 years. Maturitas, 2021, 146, 18-25.	2.4	9

#	Article	IF	CITATIONS
91	Intensive blood pressure-lowering strategy should also be offered to older patients. Journal of Hypertension, 2021, 39, 812-813.	0.5	1
92	The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis. Inflammopharmacology, 2021, 29, 641-644.	3.9	13
93	The coincidence of increased risk of atrial fibrillation in randomized control trials of omega-3 fatty acids: a meta-analysis. Expert Review of Clinical Pharmacology, 2021, 14, 773-775.	3.1	4
94	Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a metaâ€analysis. Journal of Thrombosis and Thrombolysis, 2021, 52, 124-129.	2.1	28
95	Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature. Frontiers in Public Health, 2021, 9, 628744.	2.7	46
96	Interferon-based therapies in COVID-19. International Immunopharmacology, 2021, 93, 107415.	3.8	4
97	Analysis of hospital antimicrobial consumption to identify targets for antimicrobial stewardship. Infection Control and Hospital Epidemiology, 2021, , 1-3.	1.8	3
98	Cerebral venous thrombosis following COVID-19 vaccination. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105866.	1.6	1
99	Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Comprehensive Clinical Medicine, 2021, 3, 1691-1695.	0.6	36
100	Pharmacist-patient communication amid COVID-19 pandemic: A review of available options and potential impact. British Journal of Pharmacy, 2021, 6, .	0.3	4
101	Corticosteroid Plus Tocilizumab in COVID-19. Chest, 2021, 159, 2108-2109.	0.8	1
102	Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Hypertension Research, 2021, 44, 1042-1045.	2.7	11
103	Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19. Mayo Clinic Proceedings, 2021, 96, 1365-1367.	3.0	3
104	Special consideration in the dosing of medications for patients with COVID-19 and acute kidney injury. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 690-691.	1.5	0
105	Residential Medication Management Reviews and continuous polypharmacy among older Australian women. International Journal of Clinical Pharmacy, 2021, 43, 1619-1629.	2.1	3
106	Quality of clinical practice guidelines for the management of hypertension in six Southeast Asian countries. Clinical and Experimental Hypertension, 2021, 43, 633-641.	1.3	1
107	Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. Journal of Infection, 2021, 83, e14-e15.	3.3	13
108	Innovating medication reviews through a technology-enabled process. Research in Social and Administrative Pharmacy, 2021, 18, 2700-2700.	3.0	1

#	Article	IF	CITATIONS
109	Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. Expert Review of Respiratory Medicine, 2021, 15, 1049-1055.	2.5	17
110	Concordance of recommendations across clinical practice guidelines for the management of hypertension in Southeast Asia with internationally reputable sources. BMC Cardiovascular Disorders, 2021, 21, 354.	1.7	3
111	Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology, 2021, 29, 1075-1090.	3.9	55
112	A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19. Therapie, 2021, 76, 361-364.	1.0	10
113	The impact of clinical pharmacist services on patient health outcomes in Pakistan: a systematic review. BMC Health Services Research, 2021, 21, 859.	2.2	21
114	Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. American Journal of Therapeutics, 2021, 28, e616-e619.	0.9	4
115	An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan. Vaccine, 2021, 39, 5251-5253.	3.8	11
116	Home Medicines Review and frailty among community-dwelling older women. International Journal of Pharmacy Practice, 2021, 29, 548-555.	0.6	0
117	The economic impact of pharmacist care for people living with HIV/AIDS: A systematic review. Exploratory Research in Clinical and Social Pharmacy, 2021, 3, 100066.	1.0	4
118	Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN, 2021, 45, 26-32.	1.2	18
119	Frailty and potentially inappropriate medications using the 2019 Beers Criteria: findings from the Australian Longitudinal Study on Women's Health (ALSWH). Aging Clinical and Experimental Research, 2021, 33, 2499-2509.	2.9	7
120	Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS oVâ€2 in the respiratory tract. Pharmacology Research and Perspectives, 2021, 9, e00698.	2.4	14
121	Statin use in patients with diabetes amid COVID-19 pandemic. Diabetes and Metabolism, 2021, 48, 101298.	2.9	1
122	Ingestion of betaâ€glucans could stimulate longerâ€lasting cellular immunity upon administration of COVIDâ€19 vaccines. Journal of Food Biochemistry, 2021, 45, e13959.	2.9	0
123	Impact of Multidisciplinary Team Escalating Approach on Antibiotic Stewardship in the United Arab Emirates. Antibiotics, 2021, 10, 1289.	3.7	8
124	Prevalence of frailty in patients with COVID-19: a meta-analysis. Journal of Frailty & Aging,the, 2021, 10, 1-2.	1.3	5
125	Colchicine for COVID-19: Hype or hope?. European Journal of Internal Medicine, 2021, , .	2.2	1
126	Perception, Attitude, and Confidence of Physicians About Antimicrobial Resistance and Antimicrobial Prescribing Among COVID-19 Patients: A Cross-Sectional Study From Punjab, Pakistan. Frontiers in Pharmacology, 2021, 12, 794453.	3.5	8

#	Article	IF	CITATIONS
127	SARS-CoV-2 infection pattern, transmission and treatment: Multi-center study in low to middle-income districts hospitals in Punjab, Pakistan. Pakistan Journal of Pharmaceutical Sciences, 2021, 34, 1135-1142.	0.2	0
128	Pharmacy, pharmaceuticals and public policy: Solving the puzzle. Research in Social and Administrative Pharmacy, 2020, 16, 840-843.	3.0	4
129	Strategies to reduce insulin prescribing errors in UK hospitals: results from a national survey. Diabetic Medicine, 2020, 37, 1176-1184.	2.3	9
130	Access to medicines - a systematic review of the literature. Research in Social and Administrative Pharmacy, 2020, 16, 1166-1176.	3.0	10
131	Surveillance study of asymptomatic and presymptomatic coronavirus disease 2019 (COVID-19) in care homes in Northern Ireland. Infection Control and Hospital Epidemiology, 2020, 42, 1-3.	1.8	3
132	The community pharmacy practice change towards patient-centered care in Saudi Arabia: a qualitative perspective. Journal of Pharmaceutical Policy and Practice, 2020, 13, 59.	2.4	32
133	Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatology International, 2020, 40, 2117-2118.	3.0	25
134	Use and validation of a survey tool to measure the perceived effectiveness of insulin prescribing safety interventions in UK hospitals. Diabetic Medicine, 2020, 37, 2027-2034.	2.3	1
135	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. International Journal of Infectious Diseases, 2020, 101, 107-120.	3.3	9
136	The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVIDâ€19. Obesity, 2020, 28, 2035-2035.	3.0	1
137	Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105222.	1.6	9
138	Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?. Clinical Infectious Diseases, 2020, 73, 164-165.	5.8	0
139	Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opinion on Drug Safety, 2020, 19, 1173-1191.	2.4	37
140	Montelukast in children with allergic rhinitis amid COVIDâ€19 pandemic. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 2151-2151.	1.5	3
141	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. Journal of Drug Targeting, 2020, 28, 683-699.	4.4	26
142	Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. Expert Review of Cardiovascular Therapy, 2020, 18, 475-485.	1.5	4
143	Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Review of Respiratory Medicine, 2020, 14, 1149-1163.	2.5	184
144	Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 814-821.	2.1	92

#	Article	IF	CITATIONS
145	Meta-analysis of Effect of Statins in Patients with COVID-19. American Journal of Cardiology, 2020, 134, 153-155.	1.6	149
146	The Use of Pharmacological Preventive Therapy for Migraine With Weight Gain Potential Amid Coronavirus Disease 2019 Pandemic. Headache, 2020, 60, 2085-2086.	3.9	0
147	Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2020, 20, 571-590.	2.2	34
148	Use of Azithromycin in COVID-19: A Cautionary Tale. Clinical Drug Investigation, 2020, 40, 989-990.	2.2	10
149	Pharmacotherapeutic considerations for systemic rheumatic diseases amid the COVID-19 pandemic: more questions than answers. Drugs and Therapy Perspectives, 2020, 36, 518-522.	0.6	1
150	Optimal time for the resumption of biologics after COVID-19. JAAD International, 2020, 1, 189.	2.2	1
151	Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis. Infection, 2020, 48, 805-806.	4.7	12
152	Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respiratory Medicine, 2020, 170, 106045.	2.9	32
153	Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths―Nutrients 2020, 12(4), 988. Nutrients, 2020, 12, 1626.	4.1	20
154	Use of statins in patients with COVID-19. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 604-605.	0.5	4
155	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. American Journal of Cardiovascular Drugs, 2020, 20, 301-309.	2.2	24
156	Metformin use amid coronavirus disease 2019 pandemic. Journal of Medical Virology, 2020, 92, 2401-2402.	5.0	12
157	Use of low-molecular-weight heparin in COVID-19 patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 900-901.	1.6	24
158	Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries. Research in Social and Administrative Pharmacy, 2020, 16, 1754-1759.	3.0	2
159	Role of frailty in COVID-19 patients. Intensive Care Medicine, 2020, 46, 1956-1957.	8.2	3
160	Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2020, 31, 1917-1918.	6.1	4
161	Drug burden index, polypharmacy and patient health outcomes in cognitively intact older residents of aged care facilities in Malaysia. Journal of Pharmacy Practice and Research, 2020, 50, 13-21.	0.8	4
162	Exploration of a New Source of Sustainable Nanomaterial from the Koh-e-Suleiman Mountain Range of Pakistan for Industrial Applications. Scientific Reports, 2020, 10, 577.	3.3	5

#	Article	IF	CITATIONS
163	Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. American Journal of Cardiovascular Drugs, 2020, 20, 217-221.	2.2	23
164	Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Scientific Reports, 2020, 10, 5814.	3.3	129
165	Dexamethasone or hydrocortisone in COVID-19?. Cleveland Clinic Journal of Medicine, 2020, 87, 715-715.	1.3	9
166	Is it worth the wait? Should Chloroquine or Hydroxychloroquine be allowed for immediate use in CoViD-19?. British Journal of Pharmacy, 2020, 5, .	0.3	2
167	Systematic Reviews and Meta-Analysis in Pharmacy Practice. , 2020, , 237-250.		1
168	Smoking Cessation Amid the Coronavirus 2019 Pandemic: Making Every Contact Count. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 300-302.	0.7	1
169	Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications. Cardiac Failure Review, 2020, 6, e32.	3.0	0
170	Concurrent Antibiotic Therapy in Disseminated Strongyloidiasis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 2149-2149.	1.4	3
171	Use of Pharmacologic Agents With Weight Gain Potential for Panic Disorder Amid the COVID-19 Pandemic. primary care companion for CNS disorders, The, 2020, 22, .	0.6	Ο
172	Cost analysis of type 2 diabetes mellitus treatment in economically developed countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 5-14.	1.4	17
173	Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review. Research in Social and Administrative Pharmacy, 2019, 15, 231-243.	3.0	13
174	Medicines policy issues for Saudi Arabia: priorities and model. Journal of Pharmaceutical Health Services Research, 2019, 10, 443-445.	0.6	2
175	The relationship between sleep quality, inappropriate medication use and frailty among older adults in aged care homes in Malaysia. PLoS ONE, 2019, 14, e0224122.	2.5	27
176	Anticholinergic Burden, Sleep Quality and Health Outcomes in Malaysian Aged Care Home Residents. Pharmacy (Basel, Switzerland), 2019, 7, 143.	1.6	7
177	Use of Central Nervous System (CNS) Medicines in Aged Care Homes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 1292.	2.4	10
178	Glycemic control through pharmaceutical care: a meta-analysis of randomized controlled trials. Journal of Pharmaceutical Health Services Research, 2019, 10, 35-44.	0.6	3
179	Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018. Primary Care Diabetes, 2019, 13, 409-421.	1.8	13
180	A systematic review of patientâ€reported outcomes associated with the use of directâ€acting oral anticoagulants. British Journal of Clinical Pharmacology, 2019, 85, 2652-2667.	2.4	28

#	Article	IF	CITATIONS
181	Interventions to improve insulin prescribing practice for people with diabetes in hospital: a systematic review. Diabetic Medicine, 2019, 36, 948-960.	2.3	18
182	Extensively drug-resistant typhoid fever in Pakistan. Lancet Infectious Diseases, The, 2019, 19, 242-243.	9.1	38
183	The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries. Frontiers in Pharmacology, 2019, 10, 1375.	3.5	37
184	Community pharmacist's knowledge, attitude, roles and practices towards patient-centred care in Saudi Arabia: a systematic review of the literature. Journal of Pharmaceutical Health Services Research, 2019, 10, 101-115.	0.6	15
185	Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in Health Regional Issues, 2019, 18, 18-23.	1.2	20
186	Medicine Prices in Asia–Pacific Countries. , 2019, , 45-60.		2
187	A comparison of warfarin monitoring service models. Research in Social and Administrative Pharmacy, 2019, 15, 1236-1242.	3.0	1
188	Clinical trials in Asia: A World Health Organization database study. Perspectives in Clinical Research, 2019, 10, 121.	1.0	14
189	Consolidated Medication Review Algorithm to Improve Medications Use in Older Adults: Components, Scoring Scheme, and Implementation. Journal of the American Medical Directors Association, 2018, 19, 717-718.	2.5	6
190	Health care for all: effective, community supported, healthcare with innovative use of telemedicine technology. Journal of Pharmaceutical Policy and Practice, 2018, 11, 3.	2.4	8
191	A Scoping Review of the Quality and the Design of Evaluations of Mobile Health, Telehealth, Smart Pump and Monitoring Technologies Performed in a Pharmacy-Related Setting. Frontiers in Pharmacology, 2018, 9, 678.	3.5	15
192	Associations between Drug Burden Index, medication appropriateness and patient-reported outcomes in the community pharmacy setting in Malaysia. Drugs and Therapy Perspectives, 2018, 34, 437-443.	0.6	2
193	Patients' involvement in the care process: time to value nontraditional indicators in <scp>HIV</scp> care. HIV Medicine, 2018, 19, e68.	2.2	0
194	Adherence of safety information on overâ€theâ€counter product labels and leaflets to the regulatory guidelines in Malaysia. Journal of Pharmacy Practice and Research, 2018, 48, 204-211.	0.8	3
195	Association between beliefs about medicines and self-medication with analgesics among patients with dental pain. PLoS ONE, 2018, 13, e0201776.	2.5	9
196	Academic dishonesty among academics in Malaysia: a comparison between healthcare and non-healthcare academics. BMC Medical Education, 2018, 18, 168.	2.4	13
197	Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 371-377.	1.4	4

Access to High Cost Medicines: An Overview. , 2018, , 1-10.

0

#	Article	IF	CITATIONS
199	Assessment of attitudes for interprofessional team working and knowledge of health professions competencies for final year health professional students. Asia Pacific Scholar, 2018, 3, 27-37.	0.4	6
200	Attitudes and barriers towards HIV screening: A qualitative study of people living with HIV/AIDS (PLWHA) in Malaysia. Journal of Infection Prevention, 2017, 18, 242-247.	0.9	6
201	Patients' Perceptions of Dental Students' Empathic, Person entered Care in a Dental School Clinic in Malaysia. Journal of Dental Education, 2017, 81, 404-412.	1.2	11
202	Residential Aged Care Medication Review to Improve the Quality ofÂMedication Use: A Systematic Review. Journal of the American Medical Directors Association, 2017, 18, 87.e1-87.e14.	2.5	45
203	Economic evaluation of pharmacist-led medication reviews in residential aged care facilities. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 431-439.	1.4	17
204	An Evaluation of the Central Nervous System Medication Use and Frailty among Residents of Aged Care Homes in Malaysia. Neuroepidemiology, 2017, 49, 82-90.	2.3	10
205	An evaluation of medication appropriateness and frailty among residents of aged care homes in Malaysia. Medicine (United States), 2017, 96, e7929.	1.0	28
206	Publish or Perish: A Mandate With Negative Collateral Consequences. Academic Medicine, 2017, 92, 140-140.	1.6	10
207	Implementing professionalism by deprofessionalized strategies: A moral quandary. Currents in Pharmacy Teaching and Learning, 2017, 9, 9-11.	1.0	0
208	Psychological health and menopause-specific quality of life of Malaysian women with type 2 diabetes. Asian Journal of Psychiatry, 2016, 23, 56-63.	2.0	8
209	Factors associated with poor CD4 and viral load outcomes in patients with HIV/AIDS. Journal of Medical Virology, 2016, 88, 790-797.	5.0	9
210	Anxiety symptoms and the risk of diabetes mellitus in Australian women: evidence from 21-year follow-up. Public Health, 2016, 130, 21-28.	2.9	14
211	Beliefs and practices of complementary and alternative medicine (CAM) among HIV/AIDS patients: A qualitative exploration. European Journal of Integrative Medicine, 2016, 8, 41-47.	1.7	5
212	Perceived sources of stress among Malaysian dental students. International Journal of Medical Education, 2015, 6, 56-61.	1.2	53
213	The health professionals' right to refuse: is it good, bad or ugly?. International Journal of Pharmacy Practice, 2015, 23, 92-92.	0.6	5
214	Relation between mental health-related variables and glycemic control in Malaysian women with type 2 diabetes mellitus (T2DM). International Journal of Diabetes in Developing Countries, 2015, 35, 211-218.	0.8	2
215	The validity of personal disturbance scale (DSSI/sAD) in people with diabetes mellitus, using longitudinal data. Personality and Individual Differences, 2015, 72, 182-188.	2.9	2
216	Consumer knowledge and perceptions about antibiotics and upper respiratory tract infections in a community pharmacy. International Journal of Clinical Pharmacy, 2015, 37, 1213-1221.	2.1	23

#	Article	IF	CITATIONS
217	Diabetes Mellitus and the Risk of Depressive and Anxiety Disorders in Australian Women: A Longitudinal Study. Journal of Women's Health, 2015, 24, 889-898.	3.3	25
218	Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics. Public Health, 2015, 129, 954-962.	2.9	26
219	Incidence and Risk of Depression Associated with Diabetes in Adults: Evidence from Longitudinal Studies. Community Mental Health Journal, 2015, 51, 204-210.	2.0	44
220	A comparative drug utilisation study of the treatment of diabetes in Malaysia and Australia. Australasian Medical Journal, 2015, 8, 179-188.	0.1	5
221	Psychological Health and the Risk of Diabetes Mellitus in Australian Women: A 21-Year Prospective Study. Journal of Women's Health, 2014, 23, 912-919.	3.3	4
222	The validity of the Menopause-specific Quality of Life questionnaire in women with type 2 diabetes. Climacteric, 2014, 17, 456-464.	2.4	11
223	Incidence and risk of diabetes mellitus associated with depressive symptoms in adults: Evidence from longitudinal studies. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 82-87.	3.6	19
224	Population impact of depression either as a risk factor or consequence of type 2 diabetes in adults: A meta-analysis of longitudinal studies. Asian Journal of Psychiatry, 2013, 6, 460-472.	2.0	26
225	Pregnancy complications, mental health-related problems and type 2 diabetes mellitus in Malaysian women. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2013, 7, 191-197.	3.6	4
226	Perceived impact of clinical placements on students' preparedness to provide patient-centered care in Malaysia. Currents in Pharmacy Teaching and Learning, 2013, 5, 303-310.	1.0	9
227	Response to Letter to the Editor: Factors Affecting Warfarin Related Knowledge and INR Control of Patients Attending Physicians and Pharmacists' Managed Anticoagulation Clinics. Journal of Pharmacy Practice, 2012, 25, 111-112.	1.0	0
228	People living with HIV /AIDS (PLWHA) and HIV/AIDS associated oral lesions; a study in Malaysia. BMC Public Health, 2012, 12, 850.	2.9	10
229	Perceptions and self-use of Complementary and Alternative Medicine (CAM) among Malaysian dental students. European Journal of Integrative Medicine, 2012, 4, e63-e69.	1.7	5
230	Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting. Singapore Medical Journal, 2012, 53, 526-31.	0.6	11
231	Do variations in allocation concealment methods influence the effects found in intervention reviews?. Journal of Evidence-Based Medicine, 2011, 4, 255-258.	1.8	0
232	Understanding, perceptions and self-use of complementary and alternative medicine (CAM) among Malaysian pharmacy students. BMC Complementary and Alternative Medicine, 2011, 11, 95.	3.7	29
233	Patient-Reported Adverse Drug Reactions and Drug-Drug Interactions: A Cross-Sectional Study on Malaysian HIV/AIDS Patients. Medical Principles and Practice, 2011, 20, 265-270.	2.4	10
234	Factors Affecting Warfarin-Related Knowledge and INR Control of Patients Attending Physician- and Pharmacist-Managed Anticoagulation Clinics. Journal of Pharmacy Practice, 2011, 24, 485-493.	1.0	32

#	Article	IF	CITATIONS
235	Influences on Malaysian Pharmacy Students' Career Preferences. American Journal of Pharmaceutical Education, 2010, 74, 166.	2.1	41
236	Reasons, Perceived Efficacy, and Factors Associated with Complementary and Alternative Medicine Use Among Malaysian Patients with HIV/AIDS. Journal of Alternative and Complementary Medicine, 2010, 16, 1171-1176.	2.1	30
237	Antiepileptic drug utilisation and seizure outcome among paediatric patients in a Malaysian public hospital. Singapore Medical Journal, 2010, 51, 21-7.	0.6	11
238	Understanding of and attitudes toward epilepsy among the urban Chinese population in Malaysia. Singapore Medical Journal, 2010, 51, 290-9.	0.6	2
239	Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complementary Therapies in Clinical Practice, 2009, 15, 152-157.	1.7	146
240	An assessment of dental students' empathy levels in Malaysia. International Journal of Medical Education, 0, 4, 223-229.	1.2	33
241	Metformin therapy in COVID-19: inhibition of NETosis. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	1
242	The use of corticosteroids in patients with COVID-19 vaccine–related cerebral venous thrombosis. Neurological Sciences, 0, , .	1.9	1